CJC-1295 DAC alternatives.

10 compounds compared to CJC-1295 DAC, ranked by published evidence tier and regulatory status, not by what's marketed hardest.

Why people look for an alternative

The DAC version is chosen for duration: the maleimidopropionyl group binds it covalently to albumin after injection, so it acts far longer than the plain GHRH fragment. People look for alternatives when they discover what that duration is not backed by. It has no approval from the FDA or any major regulator, its clinical development was discontinued, US authorities have flagged it as unsuitable for pharmacy compounding, and WADA prohibits it at all times as a GH-releasing factor under category S2. Short-acting GHRH analogs are the usual next stop, but they carry the same absence of approval. Tesamorelin is the only approved compound in this mechanism class.

What you're comparing against
CJC-1295 DAC
F tier · 29/100Research / preclinical

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH).

Ranked by evidence · strongest first
  1. 01
    Tesamorelin
    A tierFDA-approved
    Egrifta

    Acts through the ghrh signalling pathway, like CJC-1295 DAC. FDA-approved.

  2. 02
    Sermorelin
    C tierResearch / preclinical

    Acts through the ghrh signalling pathway, like CJC-1295 DAC. Research / preclinical.

  3. 03
    CJC-1295
    F tierResearch / preclinical

    Acts through the ghrh signalling pathway, like CJC-1295 DAC. Research / preclinical.

  4. 04
    Mod-GRF (1-29)
    F tierResearch / preclinical
    CJC-1295 no-DAC

    Acts through the ghrh signalling pathway, like CJC-1295 DAC. Research / preclinical.

  5. 05
    Human Growth Hormone
    S tierFDA-approved
    HGH · somatropin

    Same category: growth hormone. FDA-approved.

  6. 06
    ACE-031
    D tierIn human trials
    ramatercept · ActRIIB-Fc

    Same category: growth hormone. In human trials.

  7. 07
    GHRP-1
    D tierResearch / preclinical
    growth hormone-releasing peptide-1

    Same category: growth hormone. Research / preclinical.

  8. 08
    GHRP-2
    D tierResearch / preclinical

    Same category: growth hormone. Research / preclinical.

  9. 09
    GHRP-6
    D tierResearch / preclinical

    Same category: growth hormone. Research / preclinical.

  10. 10
    Hexarelin
    D tierResearch / preclinical

    Same category: growth hormone. Research / preclinical.

How this list is built

An “alternative” here means a compound that shares CJC-1295 DAC's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.

Comparing options with your provider?

PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page
Compounds